name: Parkinson's Disease
category: Complex
parents:
- Neurodegenerative Disease
- Movement Disorder
disease_term:
  preferred_term: Parkinson disease
  term:
    id: MONDO:0005180
    label: Parkinson disease
pathophysiology:
- name: Dopaminergic Neuron Loss
  description: >
    Progressive degeneration of dopaminergic neurons in the substantia nigra
    pars compacta leads to dopamine deficiency in the striatum, causing motor
    symptoms. Symptoms appear after 60-80% neuron loss.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Dopamine Biosynthesis
    term:
      id: GO:0042416
      label: dopamine biosynthetic process
  downstream:
  - target: Resting Tremor
    evidence:
    - reference: PMID:37048085
      supports: SUPPORT
      snippet: "Tremor, shaking, movement problems, and difficulty with balance and coordination are among the hallmarks, and dopaminergic neuronal loss in substantia nigra pars compacta of the brain and aggregation of intracellular protein α-synuclein are the pathological characterizations."
      explanation: This links tremor with dopaminergic neuronal loss as part of PD hallmark pathology, supporting the downstream relationship.
  - target: Bradykinesia
    evidence:
    - reference: PMID:17955331
      supports: SUPPORT
      snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
      explanation: This establishes bradykinesia as a cardinal parkinsonian sign downstream of dopaminergic degeneration.
  - target: Rigidity
    evidence:
    - reference: PMID:17955331
      supports: SUPPORT
      snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
      explanation: This identifies rigidity as a cardinal sign of parkinsonism consistent with dopaminergic neuron loss in PD.
  - target: Postural Instability
    evidence:
    - reference: PMID:17955331
      supports: SUPPORT
      snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
      explanation: This supports impaired postural reflexes as a cardinal parkinsonian sign downstream of dopaminergic dysfunction.
  evidence:
  - reference: PMID:37048085
    supports: SUPPORT
    snippet: "Tremor, shaking, movement problems, and difficulty with balance and coordination are among the hallmarks, and dopaminergic neuronal loss in substantia nigra pars compacta of the brain and aggregation of intracellular protein α-synuclein are the pathological characterizations."
    explanation: This review confirms that dopaminergic neuronal loss in the substantia nigra pars compacta is a pathological hallmark of Parkinson's disease, supporting the core mechanism of dopaminergic neuron degeneration.
- name: Alpha-Synuclein Aggregation
  description: >
    Misfolded alpha-synuclein protein accumulates to form Lewy bodies and
    Lewy neurites. These aggregates spread through the nervous system in a
    prion-like manner, contributing to neurodegeneration.
  biological_processes:
  - preferred_term: inclusion body assembly
    term:
      id: GO:0070841
      label: inclusion body assembly
  downstream:
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:38245249
      supports: SUPPORT
      snippet: "Biochemical studies, investigation of transplanted neurons in patients with Parkinson's disease, and cell and animal model studies suggest that abnormal aggregation of α-synuclein and spreading of pathology between the gut, brainstem, and higher brain regions probably underlie the development and progression of Parkinson's disease."
      explanation: This indicates that α-synuclein aggregation drives disease development and progression, supporting downstream dopaminergic neuron loss.
  - target: Neuroinflammation
    evidence:
    - reference: PMID:36598534
      supports: SUPPORT
      snippet: "α-Syn is a crucial marker of PD, and its accumulation leads to microglia M1-like phenotype polarization, activation of NLRP3 inflammasomes, and impaired autophagy and phagocytosis in microglia."
      explanation: This links α-synuclein accumulation to microglial activation, supporting neuroinflammation as a downstream effect.
  evidence:
  - reference: PMID:38245249
    supports: SUPPORT
    snippet: "Parkinson's disease is a progressive neurodegenerative condition associated with the deposition of aggregated α-synuclein."
    explanation: This authoritative Lancet review establishes that aggregated α-synuclein deposition is a defining feature of Parkinson's disease pathogenesis.
  - reference: PMID:38245249
    supports: SUPPORT
    snippet: "Biochemical studies, investigation of transplanted neurons in patients with Parkinson's disease, and cell and animal model studies suggest that abnormal aggregation of α-synuclein and spreading of pathology between the gut, brainstem, and higher brain regions probably underlie the development and progression of Parkinson's disease."
    explanation: This provides direct evidence for the prion-like spreading mechanism of α-synuclein pathology across neural networks, supporting the mechanism of trans-neuronal propagation.
  - reference: PMID:36598534
    supports: SUPPORT
    snippet: "Parkinson's disease (PD) is the second most common neurodegenerative disease, and is characterized by accumulation of α-synuclein (α-syn)."
    explanation: Confirms that α-synuclein accumulation is a key pathological characterization of PD, reinforcing the central role of protein aggregation in disease pathology.
- name: Mitochondrial Dysfunction
  description: >
    Impaired mitochondrial function, particularly complex I deficiency,
    leads to oxidative stress and neuronal death. Multiple PD genes
    (PINK1, Parkin, DJ-1) regulate mitochondrial quality control.
  biological_processes:
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  downstream:
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:27911343
      supports: SUPPORT
      snippet: "For the past 30 years, mitochondrial dysfunction has been hypothesized to play a central role in the pathobiology of this devastating neurodegenerative disease."
      explanation: This supports mitochondrial dysfunction as a central driver of neurodegeneration in PD, consistent with dopaminergic neuron loss.
  evidence:
  - reference: PMID:38245249
    supports: SUPPORT
    snippet: "At a cellular level, abnormal mitochondrial, lysosomal, and endosomal function can be identified in both monogenic and sporadic Parkinson's disease, suggesting multiple potential treatment approaches."
    explanation: This establishes that mitochondrial dysfunction is a common cellular feature across both genetic and sporadic forms of PD, supporting its central role in disease pathogenesis.
  - reference: PMID:25611507
    supports: SUPPORT
    snippet: "Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in Parkinson's disease."
    explanation: This directly supports the role of PINK1 and Parkin genes in mitochondrial quality control and confirms that mitochondrial damage is involved in PD pathogenesis.
  - reference: PMID:27911343
    supports: SUPPORT
    snippet: "For the past 30 years, mitochondrial dysfunction has been hypothesized to play a central role in the pathobiology of this devastating neurodegenerative disease. The identifications of mutations in genes encoding PINK1 (PTEN-induced kinase 1) and Parkin (E3 ubiquitin ligase) in familial PD and their functional association with mitochondrial quality control provided further support to this hypothesis."
    explanation: This review confirms the long-standing central role of mitochondrial dysfunction in PD and validates the connection between PINK1/Parkin mutations and mitochondrial quality control defects.
- name: Neuroinflammation
  description: >
    Activated microglia and astrocytes contribute to neurodegeneration
    through release of pro-inflammatory cytokines and oxidative stress.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  downstream:
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:37048085
      supports: SUPPORT
      snippet: "Neuroinflammation has emerged as an involving mechanism at the initiation and development of PD."
      explanation: This indicates neuroinflammation contributes to PD progression, supporting dopaminergic neuron loss downstream.
  evidence:
  - reference: PMID:38245249
    supports: SUPPORT
    snippet: "Recent work has also highlighted maladaptive immune and inflammatory responses, possibly triggered in the gut, that accelerate the pathogenesis of Parkinson's disease."
    explanation: This establishes that maladaptive immune and inflammatory responses play an active role in accelerating PD pathogenesis, supporting the neuroinflammation mechanism.
  - reference: PMID:37048085
    supports: SUPPORT
    snippet: "Neuroinflammation has emerged as an involving mechanism at the initiation and development of PD. It is a complex network of interactions comprising immune and non-immune cells in addition to mediators of the immune response. Microglia, the resident macrophages in the CNS, take on the leading role in regulating neuroinflammation and maintaining homeostasis."
    explanation: This directly supports the role of microglia-mediated neuroinflammation in PD initiation and progression, confirming the importance of microglial activation in disease pathology.
  - reference: PMID:36598534
    supports: SUPPORT
    snippet: "Neuroinflammation driven by microglia is an important pathological manifestation of PD. α-Syn is a crucial marker of PD, and its accumulation leads to microglia M1-like phenotype polarization, activation of NLRP3 inflammasomes, and impaired autophagy and phagocytosis in microglia."
    explanation: This links α-synuclein accumulation to microglial activation and pro-inflammatory M1 phenotype polarization, supporting the mechanism by which neuroinflammation contributes to neurodegeneration in PD.
- name: Autophagy-Lysosome Pathway Dysfunction
  description: >
    Impairment of the autophagy-lysosome pathway disrupts clearance of misfolded
    proteins including alpha-synuclein. Multiple PD genes (GBA, LRRK2, VPS35,
    ATP13A2) regulate lysosomal function, and their mutations impair protein
    degradation capacity leading to toxic protein accumulation.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Autophagy
    term:
      id: GO:0006914
      label: autophagy
  - preferred_term: Chaperone-mediated Autophagy
    term:
      id: GO:0061684
      label: chaperone-mediated autophagy
  downstream:
  - target: Alpha-Synuclein Aggregation
    evidence:
    - reference: PMID:31761667
      supports: SUPPORT
      snippet: "α-synuclein, encoded by the SNCA gene, is degraded mainly by the ALP, and mutations/multiplications in SNCA may lead to impairment of chaperone mediated autophagy or other ALP functions."
      explanation: This shows that autophagy-lysosome pathway dysfunction impairs α-synuclein clearance, supporting aggregation downstream.
  - target: Dopaminergic Neuron Loss
    evidence:
    - reference: PMID:31761667
      supports: SUPPORT
      snippet: "In recent years, multiple lines of evidence from human genetic and molecular studies have highlighted the importance of the autophagy lysosomal pathway (ALP) in Parkinson's disease (PD)."
      explanation: This supports ALP dysfunction as a key PD mechanism contributing to neuronal degeneration.
  evidence:
  - reference: PMID:31761667
    supports: SUPPORT
    snippet: "In recent years, multiple lines of evidence from human genetic and molecular studies have highlighted the importance of the autophagy lysosomal pathway (ALP) in Parkinson's disease (PD). Genes such as GBA and LRRK2, which harbor some of the most common mutations associated with PD, have essential roles in the ALP."
    explanation: This review establishes the genetic basis for autophagy-lysosome dysfunction in PD, identifying key genes and their mechanistic roles.
- name: Gut-Brain Axis Dysfunction
  description: >
    Alterations in gut microbiota composition trigger intestinal inflammation
    and may initiate alpha-synuclein misfolding in enteric neurons. Pathological
    alpha-synuclein spreads from gut to brain via the vagus nerve, supporting
    the gut-first hypothesis of PD pathogenesis.
  cell_types:
  - preferred_term: Enteric Neuron
    term:
      id: CL:0000107
      label: autonomic neuron
  - preferred_term: Enteroendocrine Cell
    term:
      id: CL:0000164
      label: enteroendocrine cell
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Alpha-Synuclein Aggregation
    evidence:
    - reference: PMID:38245249
      supports: SUPPORT
      snippet: "Biochemical studies, investigation of transplanted neurons in patients with Parkinson's disease, and cell and animal model studies suggest that abnormal aggregation of α-synuclein and spreading of pathology between the gut, brainstem, and higher brain regions probably underlie the development and progression of Parkinson's disease."
      explanation: This links gut-to-brain spread with α-synuclein aggregation, supporting this downstream effect.
  - target: Neuroinflammation
    evidence:
    - reference: PMID:38245249
      supports: SUPPORT
      snippet: "Recent work has also highlighted maladaptive immune and inflammatory responses, possibly triggered in the gut, that accelerate the pathogenesis of Parkinson's disease."
      explanation: This supports gut-triggered immune responses as a driver of neuroinflammation in PD.
  - target: Constipation
    evidence:
    - reference: PMID:38098067
      supports: SUPPORT
      snippet: "The typical symptomatology of PD includes motor symptoms; however, a range of nonmotor symptoms, such as intestinal issues, usually occur before the motor symptoms."
      explanation: This supports constipation and other intestinal symptoms as early gut-related manifestations in PD.
  evidence:
  - reference: PMID:38098067
    supports: SUPPORT
    snippet: "Various microorganisms inhabiting the gastrointestinal tract can profoundly influence the physiopathology of the central nervous system through neurological, endocrine, and immune system pathways involved in the microbiota-gut-brain axis."
    explanation: This review establishes the gut microbiota-brain connection in PD pathophysiology.
  - reference: PMID:37449597
    supports: SUPPORT
    snippet: "The vagus nerve, the main component of the parasympathetic nervous system, is involved in the regulation of immune response, digestion, heart rate, and control of mood."
    explanation: Establishes the vagus nerve as the key anatomical connection mediating gut-brain communication in PD.
- name: Oxidative Stress
  description: >
    Excessive reactive oxygen species from dopamine metabolism and mitochondrial
    dysfunction causes lipid peroxidation, protein carbonylation, and DNA damage.
    Dopamine auto-oxidation generates toxic quinones that preferentially damage
    substantia nigra neurons.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Response to Oxidative Stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: ROS Metabolic Process
    term:
      id: GO:0072593
      label: reactive oxygen species metabolic process
  downstream:
  - target: Mitochondrial Dysfunction
  - target: Dopaminergic Neuron Loss
  - target: Alpha-Synuclein Aggregation
  evidence:
  - reference: PMID:37303175
    supports: SUPPORT
    snippet: "Reactive oxygen species (ROS)-induced oxidative stress triggers the vicious cycle leading to the degeneration of dopaminergic neurons in the nigra pars compacta."
    explanation: This review directly describes the mechanism by which oxidative stress drives dopaminergic neurodegeneration.
- name: Calcium Dysregulation
  description: >
    Substantia nigra dopaminergic neurons rely on L-type calcium channels (CaV1.3)
    for autonomous pacemaking, making them uniquely vulnerable to calcium-mediated
    toxicity. Disrupted calcium homeostasis in mitochondria, ER, and lysosomes
    contributes to oxidative stress and cell death.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Calcium Ion Homeostasis
    term:
      id: GO:0055074
      label: calcium ion homeostasis
  - preferred_term: Calcium Ion Transport
    term:
      id: GO:0070588
      label: calcium ion transmembrane transport
  downstream:
  - target: Mitochondrial Dysfunction
  - target: Oxidative Stress
  - target: Dopaminergic Neuron Loss
  evidence:
  - reference: PMID:35339179
    supports: SUPPORT
    snippet: "Calcium (Ca2+) plays a central role in regulating many cellular processes and influences cell survival."
    explanation: This review establishes the fundamental role of calcium channel dysregulation in PD pathogenesis.
- name: Endoplasmic Reticulum Stress
  description: >
    Accumulation of misfolded proteins in the ER activates the unfolded protein
    response (UPR). Chronic ER stress overwhelms protective mechanisms, triggering
    apoptotic pathways. Alpha-synuclein aggregates and GBA mutations directly
    impair ER function.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: ER Stress Response
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
  - preferred_term: Unfolded Protein Response
    term:
      id: GO:0030968
      label: endoplasmic reticulum unfolded protein response
  downstream:
  - target: Autophagy-Lysosome Pathway Dysfunction
  - target: Dopaminergic Neuron Loss
  evidence:
  - reference: PMID:38026955
    supports: SUPPORT
    snippet: "Accumulating evidence shows that endoplasmic reticulum (ER) stress occurring in the SNpc DA neurons is an early event in the development of PD."
    explanation: This review establishes ER stress as an early and central event in PD pathogenesis.
- name: Synaptic Dysfunction
  description: >
    Impaired synaptic vesicle recycling, particularly defects in clathrin-mediated
    endocytosis, represents an early feature of PD. Multiple PD genes (DNAJC6,
    SYNJ1, LRRK2) regulate synaptic vesicle trafficking, and their dysfunction
    leads to synaptic failure before overt neurodegeneration.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Synaptic Vesicle Cycle
    term:
      id: GO:0099504
      label: synaptic vesicle cycle
  - preferred_term: Synaptic Vesicle Endocytosis
    term:
      id: GO:0048488
      label: synaptic vesicle endocytosis
  downstream:
  - target: Dopaminergic Neuron Loss
  - target: Alpha-Synuclein Aggregation
  evidence:
  - reference: PMID:38595283
    supports: SUPPORT
    snippet: "Notably, several of these genes are linked to the synaptic vesicle recycling process, particularly the clathrin-mediated endocytosis pathway. This suggests that impaired synaptic vesicle recycling might represent an early feature of Parkinson's disease"
    explanation: Establishes synaptic vesicle endocytosis dysfunction as an early feature of PD.
- name: Iron Accumulation and Ferroptosis
  description: >
    Abnormal iron deposition in the substantia nigra promotes ferroptosis, an
    iron-dependent form of cell death characterized by lipid peroxidation. Iron
    catalyzes Fenton reactions generating hydroxyl radicals, and dysregulated
    iron metabolism contributes to oxidative damage.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: Iron Ion Homeostasis
    term:
      id: GO:0055072
      label: iron ion homeostasis
  - preferred_term: Ferroptosis
    term:
      id: GO:0097707
      label: ferroptotic cell death
  downstream:
  - target: Oxidative Stress
  - target: Dopaminergic Neuron Loss
  evidence:
  - reference: PMID:39218077
    supports: SUPPORT
    snippet: "Parkinson's disease (PD) is a prevalent and advancing age-related neurodegenerative disorder, distinguished by the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Iron regional deposit in SNpc is a significant pathological characteristic of PD."
    explanation: This review establishes iron accumulation as a significant pathological characteristic and mechanistic driver of PD.
- name: Blood-Brain Barrier Dysfunction
  description: >
    Altered tight junction proteins, transporter dysfunction, and alpha-synuclein
    accumulation compromise BBB integrity. BBB breakdown allows infiltration of
    peripheral immune cells and blood-borne molecules, amplifying neuroinflammation.
  cell_types:
  - preferred_term: Brain Endothelial Cell
    term:
      id: CL:0002618
      label: endothelial cell of umbilical vein
  - preferred_term: Pericyte
    term:
      id: CL:0000669
      label: pericyte
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: BBB Maintenance
    term:
      id: GO:0035633
      label: maintenance of blood-brain barrier
  - preferred_term: Vascular Permeability
    term:
      id: GO:0043114
      label: regulation of vascular permeability
  downstream:
  - target: Neuroinflammation
  - target: Dopaminergic Neuron Loss
  evidence:
  - reference: PMID:39075566
    supports: SUPPORT
    snippet: "There is increasing evidence for blood-brain barrier (BBB) alterations in Parkinson's disease (PD), the second most common neurodegenerative disorder with rapidly rising prevalence."
    explanation: This comprehensive 2024 review establishes BBB dysfunction as an emerging mechanism in PD pathogenesis.
phenotypes:
- name: Resting Tremor
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Classic "pill-rolling" tremor at rest
  phenotype_term:
    preferred_term: Resting Tremor
    term:
      id: HP:0002322
      label: Resting tremor
  evidence:
  - reference: PMID:17955331
    supports: SUPPORT
    snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
    explanation: This identifies resting tremor as a cardinal sign used to detect parkinsonism, supporting it as a core PD phenotype.
- name: Bradykinesia
  category: Neurological
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Slowness of movement, required for diagnosis
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
  evidence:
  - reference: PMID:17955331
    supports: SUPPORT
    snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
    explanation: This lists bradykinesia among the cardinal signs of parkinsonism, supporting its central role in PD.
- name: Rigidity
  category: Neurological
  frequency: VERY_FREQUENT
  notes: Cogwheel or lead-pipe rigidity
  phenotype_term:
    preferred_term: Rigidity
    term:
      id: HP:0002063
      label: Rigidity
  evidence:
  - reference: PMID:17955331
    supports: SUPPORT
    snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
    explanation: This confirms rigidity as a cardinal sign of parkinsonism relevant to PD.
- name: Postural Instability
  category: Neurological
  frequency: FREQUENT
  notes: Develops in later disease stages
  phenotype_term:
    preferred_term: Postural Instability
    term:
      id: HP:0002172
      label: Postural instability
  evidence:
  - reference: PMID:17955331
    supports: SUPPORT
    snippet: "Participants are screened in the baseline and follow-up examinations for cardinal signs of parkinsonism (resting tremor, rigidity, bradykinesia or impaired postural reflexes)."
    explanation: This supports postural instability as a cardinal parkinsonian sign captured in PD assessments.
- name: Hyposmia
  category: Sensory
  frequency: FREQUENT
  notes: Often precedes motor symptoms by years
  phenotype_term:
    preferred_term: Hyposmia
    term:
      id: HP:0004409
      label: Hyposmia
  evidence:
  - reference: PMID:24136244
    supports: SUPPORT
    snippet: "Hyposmia, identified as reduced sensitivity to odor, is a common non-motor symptom of Parkinson's disease (PD) that antedates the typical motor symptoms by several years. It occurs in ∼90% of early-stage cases of PD."
    explanation: This establishes hyposmia as a highly prevalent prodromal symptom that precedes motor symptoms, supporting its importance as an early marker of PD.
- name: Constipation
  category: Gastrointestinal
  frequency: FREQUENT
  notes: Common non-motor symptom
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:7845407
    supports: SUPPORT
    snippet: "We investigated the role of anorectal manometry in evaluating constipation and anorectal function in 15 patients with Parkinson's disease (PD) and compared results with those of 9 patients with idiopathic constipation (IC) and 8 control (C) subjects."
    explanation: This study directly evaluates constipation in PD patients, supporting constipation as a common non-motor symptom.
- name: Depression
  category: Psychiatric
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:41301797
    supports: SUPPORT
    snippet: "Depressive symptoms were similar across groups, but in prodromal PD, higher GDS scores were associated with worse UPDRS III scores (p = 0.02), as well as higher freezing and fall scores."
    explanation: This indicates depressive symptoms are present and clinically relevant in PD, supporting depression as a non-motor phenotype.
genetic:
- name: SNCA
  association: Causative
  notes: Alpha-synuclein gene, autosomal dominant forms
  evidence:
  - reference: PMID:9197268
    supports: SUPPORT
    snippet: "A mutation was identified in the alpha-synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, in the Italian kindred and in three unrelated families of Greek origin with autosomal dominant inheritance for the PD phenotype."
    explanation: This landmark 1997 Science paper identified the first SNCA mutations in familial PD with autosomal dominant inheritance, establishing SNCA as a causative gene for Parkinson's disease.
- name: LRRK2
  association: Risk Factor
  notes: Most common genetic cause of late-onset PD
  evidence:
  - reference: PMID:19945904
    supports: SUPPORT
    snippet: "The LRRK2 G2019S mutation is the most frequent known cause of familial and sporadic Parkinson's disease."
    explanation: This systematic review establishes that LRRK2 G2019S is the most common genetic cause of both familial and sporadic PD, supporting its role as the major genetic risk factor.
- name: GBA
  association: Risk Factor
  notes: Glucocerebrosidase, major genetic risk factor
  evidence:
  - reference: PMID:30097731
    supports: SUPPORT
    snippet: "DLB shares risk loci with AD, in the APOE E4 allele, and with PD, in variation at GBA and SNCA."
    explanation: This identifies GBA as a genetic risk locus shared with PD, supporting its role as a PD risk factor.
- name: PARK2
  association: Causative
  notes: Parkin gene, early-onset autosomal recessive
  evidence:
  - reference: PMID:25611507
    supports: SUPPORT
    snippet: "Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in Parkinson's disease."
    explanation: This establishes Parkin (PARK2) as a gene mutated in autosomal recessive parkinsonism, supporting its causative role.
- name: PINK1
  association: Causative
  notes: Mitochondrial kinase, autosomal recessive
  evidence:
  - reference: PMID:25611507
    supports: SUPPORT
    snippet: "Biochemical and genetic studies reveal that the products of two genes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together in the same pathway to govern mitochondrial quality control, bolstering previous evidence that mitochondrial damage is involved in Parkinson's disease."
    explanation: This identifies PINK1 mutations in autosomal recessive parkinsonism, supporting its causative role in PD.
environmental:
- name: Pesticide Exposure
  notes: Rotenone and paraquat linked to increased risk
  evidence:
  - reference: PMID:15177059
    supports: SUPPORT
    snippet: "there is general agreement that smoking and exposure to pesticides affect the probability of developing PD."
    explanation: This review supports pesticide exposure as an environmental factor influencing PD risk.
- name: Rural Living
  notes: Associated with pesticide/herbicide exposure
  evidence:
  - reference: PMID:15177059
    supports: PARTIAL
    snippet: "While clear links to rural living, dietary factors, exposure to metals, head injury, and exposure to infectious diseases during childhood have not been established, there is general agreement that smoking and exposure to pesticides affect the probability of developing PD."
    explanation: This review notes that clear links to rural living are not established, indicating mixed evidence for this risk factor.
- name: Head Trauma
  notes: Possible risk factor
  evidence:
  - reference: PMID:36781627
    supports: SUPPORT
    snippet: "The risk ratio of TBI among PD and controls by a combination of 15 studies using a random-effect model was 1.48 (95% CI 1.22-1.74)."
    explanation: This meta-analysis supports head trauma (TBI) as a risk factor for developing PD.
treatments:
- name: Levodopa/Carbidopa
  description: Gold standard treatment, replaces dopamine precursor.
  evidence:
  - reference: PMID:27577098
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review identifies L-Dopa as a core pharmacotherapy for PD motor symptoms.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Dopamine Agonists
  description: Directly stimulate dopamine receptors.
  evidence:
  - reference: PMID:27577098
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review identifies dopamine agonists as part of standard pharmacotherapy for PD.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: MAO-B Inhibitors
  description: Prevent dopamine breakdown (selegiline, rasagiline).
  evidence:
  - reference: PMID:27577098
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review lists MAO-B inhibitors among standard PD pharmacotherapies.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: COMT Inhibitors
  description: Extend levodopa duration (entacapone).
  evidence:
  - reference: PMID:27577098
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review lists COMT inhibitors among standard PD pharmacotherapies.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Deep Brain Stimulation
  description: Surgical therapy for advanced motor fluctuations.
  evidence:
  - reference: PMID:27577098
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review identifies deep brain stimulation as a standard symptomatic therapy for PD.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Physical Therapy
  description: Maintains mobility and reduces fall risk.
  evidence:
  - reference: PMID:27577098
    supports: SUPPORT
    snippet: "The symptomatic treatment of the motor symptoms of Parkinson disease (PD) has been constantly optimized using pharmacotherapy (L-Dopa, several dopamine agonists, inhibitors of monoamine oxidase (MAO)-B and catechol-o-methyltransferase (COMT), and amantadine), deep brain stimulation, and physiotherapy."
    explanation: This review lists physiotherapy as part of symptomatic treatment for PD.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
datasets:
# Parkinson's Disease Gut Microbiome Studies
- accession: sra:PRJNA834801
  title: Large-scale metagenomics of Parkinson's disease gut microbiome
  description: >-
    Shotgun metagenomics from the NeuroGenetics Research Consortium (NGRC)
    with over 30% of species, genes and pathways showing altered abundances
    in PD. Identified polymicrobial clusters and competitive relationships.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
    - preferred_term: fecal sample
      term:
        id: OBI:0002503
        label: feces specimen
      tissue_term:
        preferred_term: feces
        term:
          id: UBERON:0001988
          label: feces
  conditions:
    - Parkinson's disease
    - healthy controls
  publication: PMID:36357667
  notes: Nature Communications 2022 - largest PD metagenomics to date
  evidence:
  - reference: PMID:37449597
    supports: SUPPORT
    snippet: "This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."
    explanation: This supports the relevance of gut microbiome datasets to PD mechanisms.

- accession: sra:PRJNA782492
  title: Multi-omics analysis of PD gut microbiome gene expression
  description: >-
    Integrated metagenomics and metatranscriptomics analyzing microbiome gene
    co-expression networks in Parkinson's disease. Observed significant
    depletion of hub genes in PD patients.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
    - preferred_term: fecal sample
      term:
        id: OBI:0002503
        label: feces specimen
      tissue_term:
        preferred_term: feces
        term:
          id: UBERON:0001988
          label: feces
  conditions:
    - Parkinson's disease
    - healthy controls
  notes: npj Biofilms and Microbiomes 2025 - multi-omics approach
  evidence:
  - reference: PMID:37449597
    supports: SUPPORT
    snippet: "This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."
    explanation: This supports the relevance of gut microbiome datasets to PD mechanisms.

- accession: sra:PRJNA808166
  title: Longitudinal gut microbiome in Parkinson's disease
  description: >-
    Longitudinal study investigating gut microbiome changes in PD patients
    and impact of device-assisted therapies. Tracks microbiome alterations
    with disease progression.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  sample_types:
    - preferred_term: fecal sample
      term:
        id: OBI:0002503
        label: feces specimen
      tissue_term:
        preferred_term: feces
        term:
          id: UBERON:0001988
          label: feces
  conditions:
    - Parkinson's disease baseline
    - Parkinson's disease follow-up
  notes: Frontiers Aging Neuroscience 2022 - longitudinal design
  evidence:
  - reference: PMID:37449597
    supports: SUPPORT
    snippet: "This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."
    explanation: This supports the relevance of gut microbiome datasets to PD mechanisms.

- accession: sra:PRJNA530401
  title: PD gut microbiome meta-analysis cohort
  description: >-
    Metagenomic sequencing data from PD patients and controls contributing
    to cross-cohort meta-analyses. Identified alterations linked to
    intestinal inflammation including reduced butyrate producers.
  organism:
    preferred_term: human gut metagenome
    term:
      id: NCBITaxon:408170
      label: human gut metagenome
  data_type: WGS
  sample_types:
    - preferred_term: fecal sample
      term:
        id: OBI:0002503
        label: feces specimen
      tissue_term:
        preferred_term: feces
        term:
          id: UBERON:0001988
          label: feces
  conditions:
    - Parkinson's disease
    - healthy controls
  notes: npj Parkinson's Disease 2021 - meta-analysis contributing cohort
  evidence:
  - reference: PMID:37449597
    supports: SUPPORT
    snippet: "This critical review of the literature shows that there is a close link between the microbiome, the gut, and the brain in Parkinson's disease."
    explanation: This supports the relevance of gut microbiome datasets to PD mechanisms.
computational_models:
- name: Alpha-Synuclein Aggregation BST Model
  description: >
    Biochemical Systems Theory (BST) model of alpha-synuclein aggregation kinetics
    in dopaminergic neurons. Integrates dopamine metabolism, ubiquitin-proteasome
    system, and lysosomal degradation pathways. Simulates effects of oxidative
    stress and proteasome inhibition on synuclein accumulation.
  model_type: KINETIC
  repository_url: https://www.ebi.ac.uk/biomodels/BIOMD0000000575
  model_id: BIOMD0000000575
  publication: PMID:19136028
  notes: First comprehensive kinetic model of PD-related protein aggregation
- name: Whole Dopaminergic Neuron SBML Model
  description: >
    Large-scale Systems Biology Markup Language (SBML) model of dopaminergic
    neuron containing 139 reactions and 111 metabolites. Captures dopamine
    synthesis, vesicular storage, release, reuptake, and degradation alongside
    mitochondrial function and oxidative stress.
  model_type: KINETIC
  repository_url: https://www.ebi.ac.uk/biomodels/MODEL1302200000
  model_id: MODEL1302200000
  publication: PMID:24196439
  model_format: SBML
  notes: Enables simulation of drug effects on dopaminergic neurotransmission
- name: Basal Ganglia Spiking Neural Network
  description: >
    Computational model of the basal ganglia circuit capturing dopamine-modulated
    dynamics between striatum, globus pallidus, subthalamic nucleus, and
    substantia nigra. Simulates pathological beta-band oscillations and motor
    dysfunction in PD.
  model_type: PHYSIOLOGICAL
  publication: PMID:29666208
  notes: Models circuit-level effects of dopamine depletion and DBS therapy
- name: Alpha-Synuclein Prion-like Spreading Model
  description: >
    Network diffusion model simulating prion-like propagation of misfolded
    alpha-synuclein through brain connectome. Uses graph-theoretical approach
    to predict spatial patterns of neurodegeneration from initial seeding sites.
  model_type: AGENT_BASED
  notes: Predicts Braak staging patterns from connectivity-based spreading
